Currently Viewing:
National Association of ACOs Fall 2018
Dr Joe Antos: CMS' Proposed MSSP Changes Don't Account for Variability in Healthcare
October 04, 2018
Innovative Strategies Can Boost ACO Provider Engagement, Performance
October 05, 2018
Tying Social Determinants of ACO Patients With High-Need, High-Cost Care
October 05, 2018
Dr Clif Gaus Highlights Excitement and Anxiety at NAACOS Fall 2018 Meeting
October 06, 2018
Dr Rob Fields Discusses How the Proposed MSSP Changes Impact Decisions Around ACOs
October 08, 2018
Predictability and Simplicity Needed to Help ACOs Take on Risk, Panelists Say at NAACOS
October 08, 2018
Are Commercial Payers Experiencing Success With ACO Partnerships?
October 08, 2018
Dr Katherine Schneider on Handling Variability in ACO Contracts
October 10, 2018
Stephen Nuckolls: 2 Years Isn't Enough Time for an ACO to Take on Risk
October 14, 2018
Dr Clif Gaus: Private Payer Engagement in ACOs Is Up
October 15, 2018
Allison Brennan: Trump's Administration Is Encouraging Risk, but Possibly Too Quickly
October 16, 2018
Dr Joe Antos: Proposed MSSP Changes Not a Major Shift in Policy for ACOs
October 18, 2018
Dr Rob Fields Discusses Why More ACOs Might Turn to Medicare Advantage
October 21, 2018
Stephen Nuckolls Outlines His Greatest Challenges and Opportunities of the Proposed MSSP Changes
October 22, 2018
Dr Katherine Schneider Highlights How Proposed MSSP Changes Build Stability Into Program
October 27, 2018
Allison Brennan Highlights Areas of Opportunity With Proposed MSSP Changes
October 28, 2018
Dr Rob Fields: Proposed MSSP Changes Likely to Stifle ACO Movement, Increase Consolidation
October 30, 2018
Dr Clif Gaus Discusses Measuring MSSP ACOs Savings
October 31, 2018
Dr Joe Antos: Attention Needs to Be on the Future Sustainability of Medicare
November 03, 2018
Dr Katherine Schneider: MSSP Proposed Changes Will Be a Step Back on Path to Value
November 07, 2018
Stephen Nuckolls Discusses What May Change Under the Proposed Pathways to Success
November 10, 2018
Allison Brennan Outlines the Greatest Challenges of the Proposed MSSP Changes
November 11, 2018
Dr Rob Fields Highlights Areas for Continued Innovation With ACOs
November 17, 2018
Currently Reading
Dr Joe Antos Dissects the Challenge of Addressing Drug Prices
November 23, 2018

Dr Joe Antos Dissects the Challenge of Addressing Drug Prices

The way Washington, DC, works will make it difficult to enact any meaningful change that will cause a difference in how much patients pay for prescription drugs, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.


The way Washington, DC, works will make it difficult to enact any meaningful change that will cause a difference in how much patients pay for prescription drugs, said Joe Antos, PhD, the Wilson H. Taylor Resident Scholar in Health Care and Retirement Policy at the American Enterprise Institute.

Transcript

How well do you think Congress and the Trump administration are pursuing policies to curb the cost of prescription drugs?

Prescription drug prices and costs are the same thing for most people. This is a huge issue in Washington, DC. It’s equally a huge issue at the pharmacy counter for the average person. Especially older people who tend to need more prescription drugs. It’s a big, big issue.

I think, as usual, Washington kind of has it wrong. What matters to the average patient is not what the overall price is, not what the list price is, it has nothing to do with the strange machinations of PBMs [pharmacy benefit managers] or drug companies or retail pharmacies. It has to do with when you go to the pharmacist and you pull out your credit card, how much do they want out of you? That’s the issue.

And I don’t think that Washington politics operates on that level that the average consumer would detect anything. For example, the administration, and also Congress, has been talking about somehow getting the rebates that are in the system behind the scenes to the patient when he or she picks up the prescription. The problem with that is: A) it’s impossible to know what that amount is; B) the likely amount per prescription is a very, very small number; C) from a political standpoint, and this is all that really matters, the average patient doesn’t know what they were going to pay in the first place. So, when you say you got $2 off: A) big deal; B) $2 off of what?

So, I think as a political move, there’s nothing there. As a move in terms of trying to get what people call greater transparency in pricing, it also kind of misses the point. Because the issue is not rebates, per say, but what the flow of funds are and who gets to keep the money among the many, many intermediaries between the drug manufacturer and the patient. There are a lot of people involved, everybody gets their cut. Where does the money go? Is there accountability? The answer is we don’t know.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!